Benralizumab approved for treatment of eosinophilic granulomatosis with polyangiitis

The FDA approved AstraZeneca’s Fasenra for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA, according to a company press release.
The approval comes after positive results from the MANDARA phase 3 trial that showed the efficacy and safety of Fasenra (benralizumab) compared with mepolizumab (Nucala, GSK), the only current FDA approved treatment for EGPA.
The MANDARA trial randomly assigned patients with EGPA and administered either a single 30 mg subcutaneous dose of benralizumab (n = 70) or three subcutaneous doses of 100 mg mepolizumab (n = 70)

The FDA approved AstraZeneca’s Fasenra for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA, according to a company press release.
The approval comes after positive results from the MANDARA phase 3 trial that showed the efficacy and safety of Fasenra (benralizumab) compared with mepolizumab (Nucala, GSK), the only current FDA approved treatment for EGPA.
The MANDARA trial randomly assigned patients with EGPA and administered either a single 30 mg subcutaneous dose of benralizumab (n = 70) or three subcutaneous doses of 100 mg mepolizumab (n = 70)